Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YKYamuna KondapallyJFJulie FortierMFMark A. Fiala

Discussion

Loading...

Member takes

Overview

Pilot study shows ctDNA detects residual tumor in multiple myeloma post-transplant, suggesting clinical utility for monitoring.

Key Points

  • To assess the feasibility of a tumor-informed ctDNA assay for monitoring measurable residual disease in multiple myeloma.
  • Pilot study with eligible myeloma patients post-autologous hematopoietic cell transplant (AHCT)
  • Utilized whole-exome sequencing to identify tumor-specific variants
  • Assessed ctDNA using a 16-plex assay at baseline and day +100 post-AHCT
  • 8 patients had successful tumor-informed ctDNA assay
  • 75% of patients were ctDNA-negative at day +100 and remained relapse-free
  • One ctDNA-positive patient at day +100 experienced early progression, suggesting risks captured by ctDNA

Cite This Study

Kondapally et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7ddhttps://doi.org/10.1182/blood-2025-2219
View Full Paper
Ask AI
Bookmark
Share